<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580592</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025EDE14T</org_study_id>
    <nct_id>NCT01580592</nct_id>
  </id_info>
  <brief_title>Cold Urticaria Treatment With Xolair</brief_title>
  <acronym>CUTEX</acronym>
  <official_title>A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urticaria is a very frequent skin condition characterised by transient wheal and flare type
      skin reactions associated with severe pruritus. Cold contact urticaria (CCU) is a frequent
      form of physical urticaria that is characterized by the development of wheal and flare type
      skin reactions due to the release of histamine and other proinflammatory mast cell mediators
      following exposure of the skin to cold. Among all physical urticaria subtypes the frequency
      of CCU varies between 5.7% and 33.8% in different studies. Physical urticarias including CCU
      are known to severely impair the quality of life of affected patients.

      The treatment of choice in CCU, as well as in other inducible forms and spontaneous
      urticaria, are non-sedating H1 antihistamines. Recent data have shown that updosing of H1
      blockers is significantly more effective in reducing symptoms in cold urticaria than
      standard-dose treatment. Thus, patients who cannot be sufficiently controlled with
      standard-dose antihistamines should receive high-dose H1 blockers up to 4 times the standard
      dose as recommended by the new international guidelines for the management of urticaria.

      Previous phase II studies in patients with chronic spontaneous urticaria have shown favorable
      results for the treatment with omalizumab (Xolair®). Proof-of-concept data from completed
      studies suggest that omalizumab improves urticaria in patients with chronic spontaneous
      urticaria who have failed treatment with H1 antihistamines as well as those who have failed
      treatment with a combination of H1 and H2 antihistamines and a leukotriene receptor
      antagonist. In addition, two case reports of patients with severe therapy refractory CCU
      treated with omalizumab reported a complete response with no urticarial symptoms after cold
      challenge. In summary, these data suggest that omalizumab may have a beneficial effect in the
      treatment of CCU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo</measure>
    <time_frame>day 70</time_frame>
    <description>The primary efficacy outcome was the change in trigger thresholds from baseline to week ten using TempTest® to assess critical temperature thresholds in °C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Physical Examinations, Laboratory Assessments, Vital Signs, and Adverse Events</measure>
    <time_frame>day 70</time_frame>
    <description>This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cold Contact Urticaria</condition>
  <arm_group>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>150mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>300mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, s.c., every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults (18 years or older) Informed consent signed and dated Able to read, understand and
        willing to sign the informed consent form and abide with study procedures Diagnosis of CCU
        lasting for at least 6 months Willing, committed and able to return for all clinic visits
        and complete all study-related procedures, including willingness to have SC injections
        administered by a qualified person In females of childbearing potential: Negative pregnancy
        test; females willing to use highly effective contraception (Pearl-Index &lt; 1). A woman will
        be considered not of childbearing potential if she is post-menopausal for greater than two
        years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or
        hysterectomy) No participation in other clinical trials 4 weeks before and after
        participation in this study

        Exclusion Criteria:

        Patients with acute urticaria Concurrent/ongoing treatment with immunosuppressives (e.g.
        systemic steroids, cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half
        lives prior to day 0, whichever is longer Significant medical condition rendering the
        patient immunocompromised or not suitable for a clinical trial Significant concomitant
        illness that would adversely affect the subject's participation or evaluation in this study
        History of malignancies within five years prior to screening other than a successfully
        treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cancer
        Presence of clinically significant laboratory abnormalities Lactating females or pregnant
        females Subjects for whom there is concern about compliance with the protocol procedures
        Any medical condition which, in the opinion of the Investigator, would interfere with
        participation in the study or place the subject at risk History of substance abuse (drug or
        alcohol) or any other factor (e.g., serious psychiatric condition) within the last 5 years
        that could limit the subject's ability to comply with study procedures Subjects who are
        detained officially or legally to an official institute Previous use of omalizumab within
        the last 6 months Intake of antihistamines or leukotriene antagonists within 7 days prior
        to visit 1 Intake of oral corticosteroids within 14 days prior to visit 1 Use of depot
        corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the
        study Known hypersensitivity to any ingredients, including excipients (sucrose, histidine,
        polysorbate 20) of the study medication or drugs related to omalizumab (e.g.: monoclonal
        antibodies, polyclonal gammaglobulin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Metz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <results_first_submitted>October 27, 2015</results_first_submitted>
  <results_first_submitted_qc>January 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2016</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Metz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo</title>
        <description>The primary efficacy outcome was the change in trigger thresholds from baseline to week ten using TempTest® to assess critical temperature thresholds in °C.</description>
        <time_frame>day 70</time_frame>
        <population>female and male</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo</title>
          <description>The primary efficacy outcome was the change in trigger thresholds from baseline to week ten using TempTest® to assess critical temperature thresholds in °C.</description>
          <population>female and male</population>
          <units>degree celcius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="7.6"/>
                    <measurement group_id="O2" value="-10.4" spread="9.4"/>
                    <measurement group_id="O3" value="-0.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.6</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>for omalizumab 150mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.9</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Physical Examinations, Laboratory Assessments, Vital Signs, and Adverse Events</title>
        <description>This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
        <time_frame>day 70</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examinations, Laboratory Assessments, Vital Signs, and Adverse Events</title>
          <description>This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.988</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Dr. Martin Metz</name_or_title>
      <organization>Charité – University of Berlin; Dpt. of Dermatology and Allergy</organization>
      <phone>+49 30 450 518 159</phone>
      <email>martin.metz@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

